Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | ELANE | P08246 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29238932 | 0.85 | NAPRT (0.61) | NAPRTPOLBSMN1; SMN2ALDH1A1NOTUM | |
| SCHEMBL5052007 | 0.85 | NAPRT (0.72) | NAPRTPOLBSMN1; SMN2ELANEALDH1A1 | |
| SCHEMBL4334502 | 0.83 | NAPRT (0.56) | NAPRTPOLBSMN1; SMN2ALDH1A1HTT | |
| SCHEMBL23907015 | 0.82 | NAPRT (0.64) | NAPRTPOLBSMN1; SMN2ALDH1A1NOTUM | |
| SCHEMBL4332546 | 0.82 | NAPRT (0.69) | NAPRTSMN1; SMN2ALDH1A1NOTUMMAPT | |
| SCHEMBL4849110 | 0.81 | NAPRT (0.68) | NAPRTSMN1; SMN2ALDH1A1MAPTKMT2A | |
| SCHEMBL3531406 | 0.81 | NAPRT (0.68) | NAPRTPOLBHTTNOTUMKMT2A | |
| SCHEMBL11049152 | 0.81 | NAPRT (0.68) | NAPRTPOLBSMN1; SMN2ALDH1A1ALOX15 | |
| SCHEMBL11005335 | 0.81 | NAPRT (0.68) | NAPRTPOLBALDH1A1HTTMAPT | |
| Antipyrine SCHEMBL20452 | 0.81 | NAPRT (1.00) | NAPRTPOLBSMN1; SMN2ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118026938-B | Pyrazolone ester compound and electrochemical synthesis method thereof | 江西本草天工科技有限责任公司 | 2024-06-28 | — | — | CN | claimed |
| CN-118026938-A | Pyrazolone ester compound and electrochemical synthesis method thereof | 江西本草天工科技有限责任公司 | 2024-05-14 | — | — | CN | claimed |
| EP-3892734-B1 | SCREENING METHODS AND THERAPEUTIC APPLICATIONS BASED ON BACTERIAL MOTILITY INHIBITION | UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) | 2024-08-28 | — | — | EP | disclosed |
| CN-118026938-B | Pyrazolone ester compound and electrochemical synthesis method thereof | 江西本草天工科技有限责任公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-118026938-A | Pyrazolone ester compound and electrochemical synthesis method thereof | 江西本草天工科技有限责任公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-3892734-A1 | SCREENING METHODS AND THERAPEUTIC APPLICATIONS BASED ON BACTERIAL MOTILITY INHIBITION | Ludwig-Maximilians-Universität München (DE) | 2021-10-13 | — | — | EP | disclosed |
| EP-3892734-A1 | SCREENING METHODS AND THERAPEUTIC APPLICATIONS BASED ON BACTERIAL MOTILITY INHIBITION | Ludwig-Maximilians-Universität München (DE) | 2021-10-13 | — | — | EP | disclosed |
| CN-110256407-B | Pyrazolone-substituted-3-hydroxyoxindole-containing derivative and preparation method thereof | 赣南师范大学 | 2020-08-25 | — | — | CN | disclosed |
| CN-110256407-A | One kind -3- hydroxyl oxoindole derivative of substitution containing pyrazolone and preparation method | 赣南师范大学 | 2019-09-20 | — | — | CN | disclosed |
| EP-2102169-A1 | INDAZOLYL ESTER AND AMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS | AstraZeneca AB (SE) | 2009-09-23 | — | — | EP | disclosed |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| WO-2008076048-A1 | INDAZOLYL ESTER AND AMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| EP-1833800-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006071730-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ASTRAZENECA AB (SE) | 2006-07-06 | — | — | WO | disclosed |
| WO-2006071730-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ASTRAZENECA AB (SE) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | GRIN1, GRM1, GRIN3A | NAPRT 2063/4885POLB 4059/4885SMN1; SMN2 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.